Ansa Biotechnologies, Inc.
New Form D on file · 2026-11-18 · the record
Before you sell to, join or invest in Ansa Biotechnologies, Inc.
MentionFox check on Ansa Biotechnologies, Inc.: only 1 source on file so far (checked 19 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/ansa-biotechnologies-inc-form-d-001596
Check Ansa Biotechnologies, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Ansa Biotechnologies, Inc. filed a Form D with the Securities and Exchange Commission on 2026-11-18.
Ansa Biotechnologies, Inc. filed a Form D notice of an exempt securities offering with the SEC on November 18, 2026. The filing reports $54.40M sold. Its industry group is Biotechnology. It names Jason Gammack (Executive Officer, Director), Daniel Lin-Arlow (Executive Officer, Director), Yanniv Dorone (Director) (SEC Form D, November 18, 2026).
Sell to companies like Ansa Biotechnologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Ansa Biotechnologies, Inc. raised on Nov 18. 137 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Linework USA INC. | $1.2B | AI and software |
| Linework USA INC. | $326M | AI and software |
| Pathos AI, Inc. | $238M | Biotech |
| Galvanize Therapeutics, Inc. | $136M | Biotech |
| Tractian Inc. | $106M | AI and software |
Selling to Ansa Biotechnologies, Inc.? See who runs it and how to reach them, plus this week's 161 other newly funded companies.
Is this your company?
New Form D on file · 2026-11-18 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Ansa Biotechnologies, Inc.
Free to see. No signup.
Get an email when Ansa Biotechnologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Ansa Biotechnologies, Inc. raises, hires or launches. No email unless you switch it on.
Watch Ansa Biotechnologies, Inc. →Get the full cited report on Ansa Biotechnologies, Inc.
What the filing shows about Ansa Biotechnologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ansa Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The weeks after a raise are when investors, other founders and press look Ansa Biotechnologies, Inc. up. FoxPlug is your startup's chief of staff: it reads your whole stack and tells you what to fix, what to say and what to skip, for founders shipping with Claude Code, Codex or Cursor. It drafts your monthly investor update from your real numbers, and its free tools need no account. GetFoxChat puts an AI operator on Ansa Biotechnologies, Inc.'s own site, named as you like, so the visitors this record sends you don't read one page and leave.
The filing gives Ansa Biotechnologies, Inc.'s address as 1198 65TH Street #250, Emeryville, CA 94608.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Ansa Biotechnologies, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Ansa Biotechnologies, Inc. See pricing
Ansa Biotechnologies, Inc. is a registered filer with the SEC (CIK 1816722) and has filed since 2025-10-02. 3 filings are on record, the latest on 2026-11-18.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Ansa Biotechnologies, Inc.'s Form D of 2026-11-18 names Jason Gammack, Daniel Lin-Arlow, Yanniv Dorone and 7 more as its officers, directors or promoters.
Its new offerings report $99.60M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 758 filings in Biotechnology, totalled by week. The dot is this raise, $54.40M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Jason Gammack is named as Executive Officer and Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
Daniel Lin-Arlow is named as Executive Officer and Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
Yanniv Dorone is named as Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
Brad Crutchfield is named as Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
Nate Cornell is named as Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
Nick Naclerio is named as Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
Chenny Zhang is named as Director on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
Matthias Arenskotter is named as Executive Officer on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
Geoff Hamilton is named as Executive Officer on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
Sebastian Palluk is named as Executive Officer on the Form D that Ansa Biotechnologies, Inc. filed with the SEC on 18 November 2026, one of 10 people that filing names.
10 people named on the filing — 5 holding an executive role and 5 as directors only.
Named as of the 2026-11-18 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Ansa Biotechnologies, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ansa Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ansa Biotechnologies, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
10 people named on this filing See who they are
Start a free 5-day trial →You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Ansa Biotechnologies, Inc.You get an alert in MentionFox the next time this company shows up.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Ansa Biotechnologies, Inc.. With no account yet, you sign up free and land on the result.
On these lists: San Francisco Bay Area raises, week of 2026-11-16 · Biotech raises, week of 2026-11-16 · Biotech raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

https://mentionfox.com/funding/ansa-biotechnologies-inc-form-d-001596